ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
Peripheral Absolute Lymphocyte Count, Breast Cancer-Specific and Overall Mortality According to Race, Ethnicity, and Breast Cancer Subtypes.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundLow absolute lymphocyte count (ALC) is associated with breast cancer-specific mortality (BCM) and overall mortality (OM) in non-Hispanic (NH) White women with triple-negative breast cancer (TNBC). However, little is known about the relationship of ALC with BCM or OM in other breast cancer subtypes, racial or ethnic groups. Here, we investigated the association of ALC with BCM and OM by breast cancer subtype and evaluated for modification by race or ethnicity.
methodsWe used the Oncoshare database, linking data from electronic medical records of academic and community institutions to data from the California Cancer Registry, to identify women diagnosed with stage I-III breast cancer in 2000-2017 who had a post-diagnosis ALC within five years. We used logistic regression to identify factors associated with low ALC(<1 K/µL) and Cox models to evaluate the association of minimum ALC (minALC) post-diagnosis with BCM and OM.
resultsIn 11,669 women, low ALC was associated with neutropenia, chemotherapy receipt, advanced stage, more comorbidities, and aggressive tumor features (all p≤0.001). Lower minALC was associated with higher OM(HR=0.96 per 1 K/µL increase, 95% CI 0.93-0.99), most strongly in TNBC(HR=0.73, 0.59-0.91). Race and ethnicity modified associations of minALC with BCM and OM (interaction p<0.001), more strongly in NH Black and Hispanic than NH White women.
conclusionsLow peripheral ALC was associated with higher OM in women with estrogen and/or progesterone receptor-positive, HER2-negative breast cancer or TNBC. IMPACT: Low ALC is more strongly associated with OM and BCM in women from minoritized racial and ethnic groups.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.